Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Chronic Myeloid Leukemia Specialty Channel

Chronic Myeloid Leukemia
Specialty Channel
News
Nilotinib, Dasatinib, or Flumatinib vs Imatinib as Frontline Therapy for Patients With Chronic-Phase Chronic Myeloid Leukemia
03/22/2024

Amber Denham

Amber Denham
According to a real-world, retrospective study, nilotinib, dasatinib, or flumatinib therapy each showed comparable efficacy, higher therapy responses and higher failure-free survival rates than imatinib among newly diagnosed patients with...
According to a real-world, retrospective study, nilotinib, dasatinib, or flumatinib therapy each showed comparable efficacy, higher therapy responses and higher failure-free survival rates than imatinib among newly diagnosed patients with...
According to a real-world,...
03/22/2024
Oncology
News
Asciminib Demonstrated Superior Efficacy and Safety Compared to Bosutinib Among Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
06/23/2023

Jordan Kadish

Jordan Kadish
Results from the ASCEMBL trial indicated that asciminib, a BCR::ABL1 inhibitor, demonstrated superior efficacy and safety compared to bosutinib among patients with Philadelphia chromosome-positive chronic myeloid leukemia.
Results from the ASCEMBL trial indicated that asciminib, a BCR::ABL1 inhibitor, demonstrated superior efficacy and safety compared to bosutinib among patients with Philadelphia chromosome-positive chronic myeloid leukemia.
Results from the ASCEMBL trial...
06/23/2023
Oncology
News
Olverembatinib Well-Tolerated in Adults With TKI-Resistant Chronic Myeloid Leukemia
10/17/2022
Olverembatinib, a novel tyrosine kinase inhibitor (TKI), was well tolerated and demonstrated significant anti-leukemic activity in adults with TKI-resistant CML-CP and CML-AP, especially those with the T315I mutation, according to results...
Olverembatinib, a novel tyrosine kinase inhibitor (TKI), was well tolerated and demonstrated significant anti-leukemic activity in adults with TKI-resistant CML-CP and CML-AP, especially those with the T315I mutation, according to results...
Olverembatinib, a novel tyrosine...
10/17/2022
Oncology
News
FDA Approves Asciminib for Ph+ CML
11/01/2021
The FDA granted accelerated approval to asciminib for the use in the treatment of patients with Ph+ CML in CP with or without the T315I mutation who were previously treated with 2 or more TKIs.
The FDA granted accelerated approval to asciminib for the use in the treatment of patients with Ph+ CML in CP with or without the T315I mutation who were previously treated with 2 or more TKIs.
The FDA granted accelerated...
11/01/2021
Oncology
Test Your Knowledge
Quiz: Which of the Following is Not a Standard of Care Treatment Option for CML?
09/10/2021
Which of the following is not a current standard of care option for the treatment of patients with CML?
Which of the following is not a current standard of care option for the treatment of patients with CML?
Which of the following is not a...
09/10/2021
Oncology
Test Your Knowledge
Quiz: Is the Major BCR-ABL1 Transcript Type Linked to Better Imatinib Response in CML?
04/20/2021
Study findings reported by researchers in Algeria suggest that b3a2 transcript may be tied to ____ (better/worse) responses to imatinib therapy in patients with chronic myeloid leukemia.
Study findings reported by researchers in Algeria suggest that b3a2 transcript may be tied to ____ (better/worse) responses to imatinib therapy in patients with chronic myeloid leukemia.
Study findings reported by...
04/20/2021
Oncology
Test Your Knowledge
Quiz: Which Treatment is Considered Gold Standard for CML-CP?
03/16/2021
According to experts, which of the following therapy options is considered the gold standard for frontline treatment of newly diagnosed chronic myeloid leukemia in chronic-phase?
According to experts, which of the following therapy options is considered the gold standard for frontline treatment of newly diagnosed chronic myeloid leukemia in chronic-phase?
According to experts, which of...
03/16/2021
Oncology
Test Your Knowledge
Quiz: Have TKIs Improved the CML Alternative Treatment Landscape?
02/17/2021
Prior to experts utilizing tyrosine kinase inhibitors as treatment for chronic myeloid leukemia, a stem cell transplant was required.
Prior to experts utilizing tyrosine kinase inhibitors as treatment for chronic myeloid leukemia, a stem cell transplant was required.
Prior to experts utilizing...
02/17/2021
Oncology
Test Your Knowledge
Quiz: What Was the Outcome of the ASCEMBL Trial?
12/23/2020
True of False: The ASCEMBL data concludes that, with ABL-specific inhibition, asciminib has a reduced rate of side effects that lead to discontinuation or dose adjustment compared to the TKI drug bosutinib, while improving the response rate...
True of False: The ASCEMBL data concludes that, with ABL-specific inhibition, asciminib has a reduced rate of side effects that lead to discontinuation or dose adjustment compared to the TKI drug bosutinib, while improving the response rate...
True of False: The ASCEMBL data...
12/23/2020
Oncology
Test Your Knowledge
Quiz: Is Imatinib Considered Gold Standard Frontline Treatment for CML-CP?
11/25/2020
True or False: Imatinib is considered the gold standard for frontline treatment of newly diagnosed chronic myeloid leukemia in chronic-phase.
True or False: Imatinib is considered the gold standard for frontline treatment of newly diagnosed chronic myeloid leukemia in chronic-phase.
True or False: Imatinib is...
11/25/2020
Oncology
Test Your Knowledge
Quiz: Is Additional FISH Testing Info in CML Overlooked?
10/28/2020
True or False: Although FISH testing has been applied to provide definitive information in chronic myeloid leukemia, additional information provided by FISH testing, such as atypical signal patterns that indicate for complicated chromosomal...
True or False: Although FISH testing has been applied to provide definitive information in chronic myeloid leukemia, additional information provided by FISH testing, such as atypical signal patterns that indicate for complicated chromosomal...
True or False: Although FISH...
10/28/2020
Oncology

Advertisement

News

News
Nilotinib, Dasatinib, or Flumatinib vs Imatinib as Frontline Therapy for Patients With Chronic-Phase Chronic Myeloid Leukemia
03/22/2024

Amber Denham

Amber Denham
According to a real-world, retrospective study, nilotinib, dasatinib, or flumatinib therapy each showed comparable efficacy, higher therapy responses and higher failure-free survival rates than imatinib among newly diagnosed patients with...
According to a real-world, retrospective study, nilotinib, dasatinib, or flumatinib therapy each showed comparable efficacy, higher therapy responses and higher failure-free survival rates than imatinib among newly diagnosed patients with...
According to a real-world,...
03/22/2024
Oncology
News
Asciminib Demonstrated Superior Efficacy and Safety Compared to Bosutinib Among Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
06/23/2023

Jordan Kadish

Jordan Kadish
Results from the ASCEMBL trial indicated that asciminib, a BCR::ABL1 inhibitor, demonstrated superior efficacy and safety compared to bosutinib among patients with Philadelphia chromosome-positive chronic myeloid leukemia.
Results from the ASCEMBL trial indicated that asciminib, a BCR::ABL1 inhibitor, demonstrated superior efficacy and safety compared to bosutinib among patients with Philadelphia chromosome-positive chronic myeloid leukemia.
Results from the ASCEMBL trial...
06/23/2023
Oncology
News
Olverembatinib Well-Tolerated in Adults With TKI-Resistant Chronic Myeloid Leukemia
10/17/2022
Olverembatinib, a novel tyrosine kinase inhibitor (TKI), was well tolerated and demonstrated significant anti-leukemic activity in adults with TKI-resistant CML-CP and CML-AP, especially those with the T315I mutation, according to results...
Olverembatinib, a novel tyrosine kinase inhibitor (TKI), was well tolerated and demonstrated significant anti-leukemic activity in adults with TKI-resistant CML-CP and CML-AP, especially those with the T315I mutation, according to results...
Olverembatinib, a novel tyrosine...
10/17/2022
Oncology
News
FDA Approves Asciminib for Ph+ CML
11/01/2021
The FDA granted accelerated approval to asciminib for the use in the treatment of patients with Ph+ CML in CP with or without the T315I mutation who were previously treated with 2 or more TKIs.
The FDA granted accelerated approval to asciminib for the use in the treatment of patients with Ph+ CML in CP with or without the T315I mutation who were previously treated with 2 or more TKIs.
The FDA granted accelerated...
11/01/2021
Oncology
News
Generic Version Yields Similar Efficacy, Safety to Imatinib in CML-CP
10/08/2020
Results from a prospective study in India show that the generic version of imatinib yields similar efficacy and safety, with lower cost, in patients with CML-CP.
Results from a prospective study in India show that the generic version of imatinib yields similar efficacy and safety, with lower cost, in patients with CML-CP.
Results from a prospective study...
10/08/2020
Oncology
News
Major BCR-ABL1 Transcript Type Linked to Better Imatinib Response in CML
09/29/2020
Study findings suggest that b3a2 transcript may be tied to better responses to imatinib therapy in patients with CML.
Study findings suggest that b3a2 transcript may be tied to better responses to imatinib therapy in patients with CML.
Study findings suggest that b3a2...
09/29/2020
Oncology
News
Michael Mauro, MD, Talks ELN/NCCN Recommendations for Patients With CML
07/18/2020
At the virtual Great Debates & Updates in Hematologic Malignancies, Michael Mauro, MD, presented on practical approaches for monitoring patients with CML as per NCCN and ELN recommendations.
At the virtual Great Debates & Updates in Hematologic Malignancies, Michael Mauro, MD, presented on practical approaches for monitoring patients with CML as per NCCN and ELN recommendations.
At the virtual Great Debates &...
07/18/2020
Oncology
News
Low-Dose TKIs Before Therapy Cessation Leave Treatment-Free Remission Rates Unscathed in CML
06/15/2020
Retrospective study findings demonstrated that, in patients with CML, administration of low-dose TKIs before TKI cessation does not impair treatment‐free remission.
Retrospective study findings demonstrated that, in patients with CML, administration of low-dose TKIs before TKI cessation does not impair treatment‐free remission.
Retrospective study findings...
06/15/2020
Oncology
News
NGS Preferable for Detecting Certain Mutations in Patients With CML
05/14/2020
Study findings support using NGS to illustrate BCR-ABL1 mutation status in patients with CML who do not respond or have warning responses to TKI therapy.
Study findings support using NGS to illustrate BCR-ABL1 mutation status in patients with CML who do not respond or have warning responses to TKI therapy.
Study findings support using NGS...
05/14/2020
Oncology
News
Switch From Imatinib to Dasatinib May Benefit Certain Patients With CML-CP
05/07/2020
Study findings suggest that switching patients with CML-CP from first-line imatinib to dasatinib may at times be beneficial.
Study findings suggest that switching patients with CML-CP from first-line imatinib to dasatinib may at times be beneficial.
Study findings suggest that...
05/07/2020
Oncology

Interactive Features

Test Your Knowledge
Quiz: Which of the Following is Not a Standard of Care Treatment Option for CML?
09/10/2021
Which of the following is not a current standard of care option for the treatment of patients with CML?
Which of the following is not a current standard of care option for the treatment of patients with CML?
Which of the following is not a...
09/10/2021
Oncology
Test Your Knowledge
Quiz: Is the Major BCR-ABL1 Transcript Type Linked to Better Imatinib Response in CML?
04/20/2021
Study findings reported by researchers in Algeria suggest that b3a2 transcript may be tied to ____ (better/worse) responses to imatinib therapy in patients with chronic myeloid leukemia.
Study findings reported by researchers in Algeria suggest that b3a2 transcript may be tied to ____ (better/worse) responses to imatinib therapy in patients with chronic myeloid leukemia.
Study findings reported by...
04/20/2021
Oncology
Test Your Knowledge
Quiz: Which Treatment is Considered Gold Standard for CML-CP?
03/16/2021
According to experts, which of the following therapy options is considered the gold standard for frontline treatment of newly diagnosed chronic myeloid leukemia in chronic-phase?
According to experts, which of the following therapy options is considered the gold standard for frontline treatment of newly diagnosed chronic myeloid leukemia in chronic-phase?
According to experts, which of...
03/16/2021
Oncology
Test Your Knowledge
Quiz: Have TKIs Improved the CML Alternative Treatment Landscape?
02/17/2021
Prior to experts utilizing tyrosine kinase inhibitors as treatment for chronic myeloid leukemia, a stem cell transplant was required.
Prior to experts utilizing tyrosine kinase inhibitors as treatment for chronic myeloid leukemia, a stem cell transplant was required.
Prior to experts utilizing...
02/17/2021
Oncology
Test Your Knowledge
Quiz: What Was the Outcome of the ASCEMBL Trial?
12/23/2020
True of False: The ASCEMBL data concludes that, with ABL-specific inhibition, asciminib has a reduced rate of side effects that lead to discontinuation or dose adjustment compared to the TKI drug bosutinib, while improving the response rate...
True of False: The ASCEMBL data concludes that, with ABL-specific inhibition, asciminib has a reduced rate of side effects that lead to discontinuation or dose adjustment compared to the TKI drug bosutinib, while improving the response rate...
True of False: The ASCEMBL data...
12/23/2020
Oncology
Test Your Knowledge
Quiz: Is Imatinib Considered Gold Standard Frontline Treatment for CML-CP?
11/25/2020
True or False: Imatinib is considered the gold standard for frontline treatment of newly diagnosed chronic myeloid leukemia in chronic-phase.
True or False: Imatinib is considered the gold standard for frontline treatment of newly diagnosed chronic myeloid leukemia in chronic-phase.
True or False: Imatinib is...
11/25/2020
Oncology
Test Your Knowledge
Quiz: Is Additional FISH Testing Info in CML Overlooked?
10/28/2020
True or False: Although FISH testing has been applied to provide definitive information in chronic myeloid leukemia, additional information provided by FISH testing, such as atypical signal patterns that indicate for complicated chromosomal...
True or False: Although FISH testing has been applied to provide definitive information in chronic myeloid leukemia, additional information provided by FISH testing, such as atypical signal patterns that indicate for complicated chromosomal...
True or False: Although FISH...
10/28/2020
Oncology
Test Your Knowledge
Quiz: Which Clinical Trial Approved the Use of Imatinib for CML?
09/25/2020
Which clinical trial displayed results that were in favor of imatinib, both in terms of efficacy and tolerability, for chronic myeloid leukemia?
Which clinical trial displayed results that were in favor of imatinib, both in terms of efficacy and tolerability, for chronic myeloid leukemia?
Which clinical trial displayed...
09/25/2020
Oncology
Test Your Knowledge
Quiz: Do Low-Dose TKIs Prior to Therapy Cessation Impair CML Remission Rates?
08/19/2020
True or False: The administration of low-dose TKIs before TKI cessation impairs treatment‐free remission in patients with CML.
True or False: The administration of low-dose TKIs before TKI cessation impairs treatment‐free remission in patients with CML.
True or False: The...
08/19/2020
Oncology
Test Your Knowledge
Quiz: Switching From Imatinib to Dasatinib in Chronic-Phase CML
07/28/2020
True or False: Switching from imatinib to dasatinib, in cases of suboptimal response, may offer clinical benefit in patients with CML.
True or False: Switching from imatinib to dasatinib, in cases of suboptimal response, may offer clinical benefit in patients with CML.
True or False: Switching from...
07/28/2020
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Recent News

News
Nilotinib, Dasatinib, or Flumatinib vs Imatinib as Frontline Therapy for Patients With Chronic-Phase Chronic Myeloid Leukemia
03/22/2024

Amber Denham

Amber Denham
According to a real-world, retrospective study, nilotinib, dasatinib, or flumatinib therapy each showed comparable efficacy, higher therapy responses and higher failure-free survival rates than imatinib among newly diagnosed patients with...
According to a real-world, retrospective study, nilotinib, dasatinib, or flumatinib therapy each showed comparable efficacy, higher therapy responses and higher failure-free survival rates than imatinib among newly diagnosed patients with...
According to a real-world,...
03/22/2024
Oncology
News
Asciminib Demonstrated Superior Efficacy and Safety Compared to Bosutinib Among Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
06/23/2023

Jordan Kadish

Jordan Kadish
Results from the ASCEMBL trial indicated that asciminib, a BCR::ABL1 inhibitor, demonstrated superior efficacy and safety compared to bosutinib among patients with Philadelphia chromosome-positive chronic myeloid leukemia.
Results from the ASCEMBL trial indicated that asciminib, a BCR::ABL1 inhibitor, demonstrated superior efficacy and safety compared to bosutinib among patients with Philadelphia chromosome-positive chronic myeloid leukemia.
Results from the ASCEMBL trial...
06/23/2023
Oncology
News
Olverembatinib Well-Tolerated in Adults With TKI-Resistant Chronic Myeloid Leukemia
10/17/2022
Olverembatinib, a novel tyrosine kinase inhibitor (TKI), was well tolerated and demonstrated significant anti-leukemic activity in adults with TKI-resistant CML-CP and CML-AP, especially those with the T315I mutation, according to results...
Olverembatinib, a novel tyrosine kinase inhibitor (TKI), was well tolerated and demonstrated significant anti-leukemic activity in adults with TKI-resistant CML-CP and CML-AP, especially those with the T315I mutation, according to results...
Olverembatinib, a novel tyrosine...
10/17/2022
Oncology
News
FDA Approves Asciminib for Ph+ CML
11/01/2021
The FDA granted accelerated approval to asciminib for the use in the treatment of patients with Ph+ CML in CP with or without the T315I mutation who were previously treated with 2 or more TKIs.
The FDA granted accelerated approval to asciminib for the use in the treatment of patients with Ph+ CML in CP with or without the T315I mutation who were previously treated with 2 or more TKIs.
The FDA granted accelerated...
11/01/2021
Oncology
News
Generic Version Yields Similar Efficacy, Safety to Imatinib in CML-CP
10/08/2020
Results from a prospective study in India show that the generic version of imatinib yields similar efficacy and safety, with lower cost, in patients with CML-CP.
Results from a prospective study in India show that the generic version of imatinib yields similar efficacy and safety, with lower cost, in patients with CML-CP.
Results from a prospective study...
10/08/2020
Oncology
News
Major BCR-ABL1 Transcript Type Linked to Better Imatinib Response in CML
09/29/2020
Study findings suggest that b3a2 transcript may be tied to better responses to imatinib therapy in patients with CML.
Study findings suggest that b3a2 transcript may be tied to better responses to imatinib therapy in patients with CML.
Study findings suggest that b3a2...
09/29/2020
Oncology
News
Michael Mauro, MD, Talks ELN/NCCN Recommendations for Patients With CML
07/18/2020
At the virtual Great Debates & Updates in Hematologic Malignancies, Michael Mauro, MD, presented on practical approaches for monitoring patients with CML as per NCCN and ELN recommendations.
At the virtual Great Debates & Updates in Hematologic Malignancies, Michael Mauro, MD, presented on practical approaches for monitoring patients with CML as per NCCN and ELN recommendations.
At the virtual Great Debates &...
07/18/2020
Oncology
News
Low-Dose TKIs Before Therapy Cessation Leave Treatment-Free Remission Rates Unscathed in CML
06/15/2020
Retrospective study findings demonstrated that, in patients with CML, administration of low-dose TKIs before TKI cessation does not impair treatment‐free remission.
Retrospective study findings demonstrated that, in patients with CML, administration of low-dose TKIs before TKI cessation does not impair treatment‐free remission.
Retrospective study findings...
06/15/2020
Oncology
News
NGS Preferable for Detecting Certain Mutations in Patients With CML
05/14/2020
Study findings support using NGS to illustrate BCR-ABL1 mutation status in patients with CML who do not respond or have warning responses to TKI therapy.
Study findings support using NGS to illustrate BCR-ABL1 mutation status in patients with CML who do not respond or have warning responses to TKI therapy.
Study findings support using NGS...
05/14/2020
Oncology
News
Switch From Imatinib to Dasatinib May Benefit Certain Patients With CML-CP
05/07/2020
Study findings suggest that switching patients with CML-CP from first-line imatinib to dasatinib may at times be beneficial.
Study findings suggest that switching patients with CML-CP from first-line imatinib to dasatinib may at times be beneficial.
Study findings suggest that...
05/07/2020
Oncology
News
Cabozantinib Shows Promising Activity Among Patients With Progressive, Unresectable Metastatic Phaeochromocytomas and Paragangliomas
04/25/2024

Stephanie Holland 

Stephanie Holland 
According to results from the phase 2 Natalie trial, cabozantinib showed promising clinical activity among patients with progressive, unresectable metastatic phaeochromocytomas and paragangliomas.
According to results from the phase 2 Natalie trial, cabozantinib showed promising clinical activity among patients with progressive, unresectable metastatic phaeochromocytomas and paragangliomas.
According to results from the...
04/25/2024
Oncology
News
Adjuvant Pembrolizumab Significantly Improved Overall Survival Among Patients With Clear-Cell Renal Cell Carcinoma at Increased Risk of Recurrence
04/25/2024

Stephanie Holland 

Stephanie Holland 
According to interim analysis results from the phase 3 KEYNOTE-564 trial, adjuvant pembrolizumab significantly improved overall survival compared to placebo among patients with clear-cell renal cell carcinoma at increased risk of recurrence...
According to interim analysis results from the phase 3 KEYNOTE-564 trial, adjuvant pembrolizumab significantly improved overall survival compared to placebo among patients with clear-cell renal cell carcinoma at increased risk of recurrence...
According to interim analysis...
04/25/2024
Oncology
News
FDA Grants Accelerated Approval to Tovorafenib for Patients With Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma
04/25/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the FIREFLY-1 trial, the FDA has granted accelerated approval to tovorafenib for patients aged 6 months and older with relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion, rearrangement, or a BRAF...
Based on results from the FIREFLY-1 trial, the FDA has granted accelerated approval to tovorafenib for patients aged 6 months and older with relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion, rearrangement, or a BRAF...
Based on results from the...
04/25/2024
Oncology
News
Lutetium Lu 177 Dotatate Gains FDA Approval for Pediatric Patients With SSTR-Positive Gastroenteropancreatic Neuroendocrine Tumors
04/24/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the NETTER-P and NETTER-1 studies, the FDA has approved lutetium Lu 177 dotatate for pediatric patients age 12 and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
Based on results from the NETTER-P and NETTER-1 studies, the FDA has approved lutetium Lu 177 dotatate for pediatric patients age 12 and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
Based on results from the...
04/24/2024
Oncology
News
Gemcitabine Plus Cisplatin and Intensity-Modulated Radiation Therapy Improved Response Rate Among Patients With Unresectable Vulvar Squamous Cell Carcinoma
04/23/2024

Stephanie Holland 

Stephanie Holland 
Results from the phase 2 NRG Oncology/GOG Study 279 found that gemcitabine plus cisplatin concurrently administered with intensity-modulated radiation therapy improved complete pathologic response among patients with locally advanced,...
Results from the phase 2 NRG Oncology/GOG Study 279 found that gemcitabine plus cisplatin concurrently administered with intensity-modulated radiation therapy improved complete pathologic response among patients with locally advanced,...
Results from the phase 2 NRG...
04/23/2024
Oncology
News
FDA Approves Nogapendekin Alfa Inbakicept for Patients With Bacillus Calmette-Guérin-Unresponsive Non-Muscle Invasive Bladder Cancer
04/23/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the phase 3 QUILT-3.032 trial, the FDA has approved nogapendekin alfa inbakicept for patients with Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer.
Based on results from the phase 3 QUILT-3.032 trial, the FDA has approved nogapendekin alfa inbakicept for patients with Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer.
Based on results from the phase...
04/23/2024
Oncology
News
FDA Approves Adjuvant Alectinib for Patients With Resected ALK-Positive Non-Small Cell Lung Cancer
04/19/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the phase 3 ALINA trial, the FDA has approved alectinib in the adjuvant setting for patients with resected ALK-positive non-small cell lung cancer.
Based on results from the phase 3 ALINA trial, the FDA has approved alectinib in the adjuvant setting for patients with resected ALK-positive non-small cell lung cancer.
Based on results from the phase...
04/19/2024
Oncology
News
IV High-Dose Methotrexate With IT Liposomal Cytarabine and R-CHOP Effective for Patients With Risk of CNS Relapse, Including DLBCL With Primary Testis Localization
04/19/2024

Amber Denham

Amber Denham
According to phase 2 results, intravenous high-dose methotrexate in combination with intrathecal liposomal cytarabine and R-CHOP is effective among patient populations with high risk of central nervous system relapse, specifically those with...
According to phase 2 results, intravenous high-dose methotrexate in combination with intrathecal liposomal cytarabine and R-CHOP is effective among patient populations with high risk of central nervous system relapse, specifically those with...
According to phase 2 results,...
04/19/2024
Oncology
News
Elranatamab vs Teclistamab Treatment Among Patients With Triple-Class Exposed/Refractory Multiple Myeloma
04/19/2024

Jordan Kadish 

Jordan Kadish 
According to findings from an unanchored matching-adjusted indirect comparison, elranatamab exhibited significantly better response and survival outcomes among patients with triple-class exposed/refractory multiple myeloma, compared with...
According to findings from an unanchored matching-adjusted indirect comparison, elranatamab exhibited significantly better response and survival outcomes among patients with triple-class exposed/refractory multiple myeloma, compared with...
According to findings from an...
04/19/2024
Oncology
News
Venetoclax Monotherapy Demonstrates Deep, Durable Responses Among Adult Patients With R/R CLL
04/18/2024

Amber Denham

Amber Denham
According to phase 3b results from the VENICE-1 trial, venetoclax monotherapy demonstrates durable responses in adult patients with relapsed/refractory chronic lymphocytic leukemia, including BCRi-pretreated patients.
According to phase 3b results from the VENICE-1 trial, venetoclax monotherapy demonstrates durable responses in adult patients with relapsed/refractory chronic lymphocytic leukemia, including BCRi-pretreated patients.
According to phase 3b results...
04/18/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement